The story of copyright's flagship drug presents a complex case for stakeholders in the medicinal sector. While initially a blockbuster success, creating vast sums, the patent lapse and the subsequent flood of off-brand alternatives have considerably affected earnings. This raises questions about the ongoing viability of similar medication develo… Read More